BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 61,397 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 61,397 shares of the firm’s stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $317.67, for a total value of $19,503,984.99. Following the sale, the chief executive officer directly owned 9,180 shares of the company’s stock, valued at approximately $2,916,210.60. This represents a 86.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The shares were sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Stock Up 1.4%

ONC stock opened at $330.46 on Wednesday. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $253.95 and a 1-year high of $385.22. The stock has a market cap of $36.26 billion, a price-to-earnings ratio of 73.93 and a beta of 0.49. The company’s 50 day moving average is $292.77 and its 200 day moving average is $309.37.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion for the quarter. Sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ONC. Truist Financial boosted their target price on BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a research report on Monday. Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Finally, Guggenheim lifted their price target on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $394.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers purchased a new position in shares of BeOne Medicines during the 2nd quarter worth $455,000. Rhumbline Advisers bought a new stake in shares of BeOne Medicines in the second quarter worth about $275,000. Arrowstreet Capital Limited Partnership purchased a new stake in BeOne Medicines during the second quarter valued at $505,000. Invesco Ltd. bought a new position in BeOne Medicines during the second quarter valued at $422,000. Finally, EverSource Wealth Advisors LLC bought a new position in shares of BeOne Medicines during the second quarter valued at approximately $68,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.